利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.028 秒)

    Universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma
    3.
    发明申请
    Universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma 审中-公开
    普遍适用的病毒灭活血浆是由非白血病部分血浆产生的

    公开(公告)号：US20070071829A1

    公开(公告)日：2007-03-29

    申请号：US10580548

    申请日：2004-12-20

    申请人： Andrea Heger ,  Jurgen Romisch ,  Tor-Einar Svae ,  Wolfgang Marguerre

    发明人： Andrea Heger ,  Jurgen Romisch ,  Tor-Einar Svae ,  Wolfgang Marguerre

    IPC分类号： A61K35/16 ,  C12N5/08

    CPC分类号： A61K35/16

    摘要： A blood plasma for human use pooled from donors which belong to 10% or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing substantial amounts of blood or blood plasma of blood group 0 characterized in that four to eight parts of blood or blood plasma from donors having the blood group A, more than three parts to seven parts of blood or blood plasma from donors having the blood group B, zero to two parts of blood or blood plasma from donors having the blood group AB.

    摘要翻译： 属于非高加索人口10％以上的供体的人血浆是通过混合血型A和B的血液或血浆而得到的血浆，任选地AB，而不混合大量的血液或血浆 的血型0，其特征在于，具有血型A，来自具有血型B的供体的血液或血浆中的血液或血浆的血液或血浆的血液或血浆中的血液或血浆的血液或血浆为4至8份，血液为零至2份 或具有血型AB的供体的血浆。

    Universally applicable virus inactivated blood plasma produced from portions of non-Caucasians plasma
    4.
    发明申请
    Universally applicable virus inactivated blood plasma produced from portions of non-Caucasians plasma 审中-公开
    普遍适用的病毒灭活血浆由部分非高加索血浆产生

    公开(公告)号：US20110104298A1

    公开(公告)日：2011-05-05

    申请号：US12805920

    申请日：2010-08-24

    申请人： Andrea Heger ,  Jürgen Römisch ,  Tor-Einar Svae ,  Wolfgang Marguerre

    发明人： Andrea Heger ,  Jürgen Römisch ,  Tor-Einar Svae ,  Wolfgang Marguerre

    IPC分类号： A61K35/16

    CPC分类号： A61K35/16

    摘要： A blood plasma for human use pooled from donors which belong to 10% or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing substantial amounts of blood or blood plasma of blood group 0 characterized in thatfour to eight parts of blood or blood plasma from donors having the blood group A,more than three parts to seven parts of blood or blood plasma from donors having the blood group B,zero to two parts of blood or blood plasma from donors having the blood group AB.

    摘要翻译： 属于非高加索人口10％以上的供体的人血浆是通过混合血型A和B的血液或血浆，任选地AB而不混合大量血液或血浆而获得的血浆 的血型0，其特征在于，具有血型A，来自具有血型B的供体的血液或血浆中的血液或血浆的血液或血浆的血液或血浆中的血液或血浆的血液或血浆为4至8份，血液为零至2份 或具有血型AB的供体的血浆。

    Universally applicable blood plasma
    5.
    发明申请
    Universally applicable blood plasma 审中-公开
    普适适用血浆

    公开(公告)号：US20070014806A1

    公开(公告)日：2007-01-18

    申请号：US11524290

    申请日：2006-09-21

    申请人： Wolfgang Marguerre ,  Tor-Einar Svae

    发明人： Wolfgang Marguerre ,  Tor-Einar Svae

    IPC分类号： A61K35/14 ,  A61K39/00 ,  A01N1/02

    CPC分类号： A61K38/16

    摘要： A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.

    摘要翻译： 一种普遍适用的血浆，其可通过包括以下步骤的方法获得：血液或血型A和B任选血液或血浆AB血液或血浆，而不混合大量来自血型0的血液或血浆。

    Universally applicable blood plasma
    6.
    发明申请
    Universally applicable blood plasma 审中-公开
    普适适用血浆

    公开(公告)号：US20110008459A1

    公开(公告)日：2011-01-13

    申请号：US12923380

    申请日：2010-09-17

    申请人： Wolfgang Marguerre ,  Tor-Einar Svae

    发明人： Wolfgang Marguerre ,  Tor-Einar Svae

    IPC分类号： A61K35/16 ,  A61P7/00

    CPC分类号： A61K35/16

    摘要： A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.

    摘要翻译： 一种普遍适用的血浆，其可通过包括以下步骤的方法获得：血液或血型A和B任选血液或血浆AB血液或血浆，而不混合大量来自血型0的血液或血浆。

    Albumin solution and process for the production thereof
    8.
    发明申请
    Albumin solution and process for the production thereof 审中-公开
    白蛋白溶液及其生产方法

    公开(公告)号：US20060234907A1

    公开(公告)日：2006-10-19

    申请号：US10544833

    申请日：2004-02-13

    申请人： Werner Gehringer ,  Katharina Pock ,  Jürgen Römisch ,  Tor-Einar Svae ,  Christoph Kannicht

    发明人： Werner Gehringer ,  Katharina Pock ,  Jürgen Römisch ,  Tor-Einar Svae ,  Christoph Kannicht

    IPC分类号： C07K14/765

    CPC分类号： A61L2/0088 ,  C07K14/765

    摘要： The invention relates to a therapeutically usable virus-inactivated albumin, and to a process for the preparation of a therapeutically usable virus-inactivated albumin, characterized by the combination of the following steps: (a) subjecting a first aqueous albumin solution to a treatment for virus inactivation by the SD method by contacting it with SD reagents at a temperature of below 45° C.; (b) removing, at least substantially, the SD reagents by oil extraction followed by hydrophobic interaction chromatography, wherein a hydrophobic matrix, especially a matrix to which hydrophobic groups may optionally be bound, is used for said chromatography, with the proviso that said groups are aliphatic groups with more than 24 carbon atoms, to obtain a second albumin solution to which (c) optionally one or more stabilizers selected from the group of sugars, amino acids and sugar alcohols are added, with the proviso that no indole stabilizer and no C6-C10 fatty acid is employed as said stabilizer, whereupon (d) said second albumin solution to which a stabilizer has optionally been added is subjected to final packaging and sterile filtration and optionally filled into final containers.

    摘要翻译： 本发明涉及治疗上可用的病毒灭活的白蛋白，以及制备治疗上可用的病毒灭活的白蛋白的方法，其特征在于以下步骤的组合：（a）使第一种含水白蛋白溶液进行治疗 通过SD方法通过在低于45℃的温度下与SD试剂接触来进行病毒灭活。 （b）通过油提取至少基本上除去SD试剂，然后通过疏水相互作用色谱法除去，其中疏水基质，特别是疏水基团可以任选地结合的基质用于所述层析，条件是所述基团 是具有超过24个碳原子的脂族基团，以获得第二白蛋白溶液，其中（c）任选地加入一种或多种选自糖，氨基酸和糖醇的稳定剂，条件是没有吲哚稳定剂和没有 使用C 6 -C 10脂肪酸作为所述稳定剂，然后（d）将任选加入稳定剂的所述第二白蛋白溶液进行最终包装并将其无菌 过滤并任选地填充到最终容器中。